



## Draft Agenda

*Conference is preceded by a by-invitation-only CEO/Investor Reception and Dinner on September 18, from 5 to 9 PM at the same Venue in Long Beach*

**7:30 AM -- Registration and Breakfast**

**8:30 AM — 8:50 AM -- Opening Remarks**

- **Ahmed Enany, President & CEO, SoCalBio**

**8:50 AM — 9:20 AM – The Bioscience Industry Funding Landscape**

*A leading investment professional provides a data-rich update on bioscience industry investment trends, particularly the funding prospects of emerging biotech, MedTech, and digital health companies.*

- **Soraya M. Scroggins, Managing Director, Investment Banking and Global Healthcare, Barclays**

**9:30 AM — 9:50 AM -- The Greater Los Angeles Biotech Hub: Why Here? Why Now?**

*The Greater Los Angeles Metro Area (including Los Angeles County, Orange County, the Inland Empire and Ventura County) is home to a growing biotech cluster that includes more than 300 companies. One of these is Dantari Pharmaceuticals (Newbury Park, CA) which was recently founded and funded by Ventura County-based VC firm Westlake Village BioPartners. Dantari's chief, Dr. Richard Markus, a seasoned biotech executive who previously worked for companies such as Amgen, Allergan and MannKind, shares his insights on what makes the Greater Los Angeles Region a fertile ground for new biotech firm formation, and how to successfully attract adequate funding to pursue bioscience R&D activities to serve unmet needs.*

- **Richard Markus, MD, PhD**, CEO, Dantari Pharmaceuticals

### **10:00 AM — 10:40 AM -- Chairman's Symposium on Made-in-LA Healthcare Innovations**

*Since WW II, the Greater Los Angeles Region has been the leading hotbed of MedTech innovations, from heart valves, stents, pacemakers and other implantables to surgical tools, medical wearables, and drug delivery devices. Los Angeles-based firms continue to spawn and commercialize MedTech breakthroughs that promise to change the face of medicine. This symposium will shed light on recent innovations based on the interface between engineering and neurosciences that may result in bionic devices to restore body functions or cure difficult-to-treat medical conditions.*

- “Medical Robotics Has an Incredibly Exciting Future: A Look at the Alfred Mann Foundation’s Bionic Arm,” by **Robert Greenberg, MD, PhD, Executive Chairman, Alfred Mann Foundation**
- “The Orion Project for Restoring Useful Vision to the Blind and Severely Visually Impaired,” by **Will McGuire, CEO, Second Sight Medical Products**
- “Neuromodulation Devices to Treat a Wide-Spectrum of Disorders, Including ADHD,” by **Ian A. Cook, MD, CMO, NeuroSigma**

### **10:40—10:50 AM -- Networking Break**

### **10:50 AM —12:15 PM -- Emerging Company Presentations**

Three Parallel Tracks of emerging biotech, device, and digital health firms making investment pitches

#### **Biotech Presentations:**

1. **IntelliStem Technologies** (Immunotherapy for cancer)
2. **Cell Care Therapeutics** (Immunotherapy for retinal disease)
3. **Capricor Therapeutics** (First-in-class biological therapies for the treatment of rare diseases)
4. **MyoGene Bio** (A UCLA startup developing gene-editing therapy for Duchenne Muscular Dystrophy)
5. **Breakthrough Genomics** (Software for interpreting whole genome and whole exome data)

### **Device Presentations:**

1. **WhisperSom Corporation** (Device for sleep apnea)
2. **Cactus Medical** (Pediatric ear care)
3. **Noninvasix, Inc.** (Optoacoustic monitoring of cerebral venous oxygenation to accurately measure the amount of oxygen a baby is receiving in real time)
4. **ReSymmetry** (Robotic wheelchair based on innovative technology)
5. **Platinum Group Coatings LLC** (High-performance electrodes for sensor and stimulator applications)
6. **Leap Biomed** (R&D to bring fundamentally new medical devices to market)

### **Digital Health Presentations:**

1. **Aspro dental** (SaaS platform that can save dentists an hour per day on managing operations and health records)
2. **Vayu Technology** (A wearable sensor and AI-driven SaaS solution that provides a wealth of biomechanics data and insights)
3. **Expy Health** (Orthopedic pre- and post-surgery patient monitoring)

**12:15 PM—12:45 PM -- Luncheon**

**12:45 PM — 1:35 PM -- Luncheon Keynote Presentation:**

*Congress passed the 21st Century Cures Act in December 2016, authorizing \$1.8 billion in NIH funding for the Cancer Moonshot over 7 years. This initiative seeks to accelerate the development of cancer cures by tapping the innovative energies of all stakeholders in the private, public and academic sectors who are engaged in oncology R&D. Learn what is new at NCI's Cancer Moonshot Initiative, and how oncology companies can benefit.*

### **Introductory Presentation:**

- **Patricia Weber, DrPH, Program Director, SBIR Development Center, NCI, NIH**

**Speakers** (each will speak about what is next in their oncology pipeline and whether the “moonshot” approach can help further R&D efforts):

- Amgen? (10 minutes)
- Kite Pharma? (10 minutes)
- Dendreon? (10 minutes)

## **1:40 PM —2:30 PM -- Recent Investment Trends in Corporate Venture Capital**

*Corporate VC funding has been on the rise lately. For larger biopharma and medical device corporations, having venture arms to invest in startups can be a way of outsourcing some of their R&D efforts in new and unproven technologies without assuming all of the costs and risks. This panel will explore if corporate interest in venture investing will persist. Also, speakers will discuss if increased corporate VC funding may benefit more startups or will it simply drive prices higher for a select few?*

### **Moderator:**

- **Joseph Boystak, Managing Partner, Health2047 Capital Partners**

### **Speakers:**

- **Kara Bortone, PhD, Sr. Director Portfolio Sourcing & Management, J&J Innovation**
- **John Donello, PhD, Vice President, Research Pharmacology, Allergan**
- **Kanad Das, PhD, Executive Director, Boehringer Ingelheim Venture USA Inc.**

## **2:30 PM —2:40 PM -- Networking Break**

## **2:40 PM—3:40 PM -- Emerging Company Presentations**

*Three Parallel Tracks of biotech, device and digital health firms making investment pitches*

### **Biotech Presentations:**

1. **Nammi Therapeutics** (Drug delivery using nanoparticles)
2. **O-Ray Pharma** (Treatment ear diseases)

### **Diagnostics & Screening:**

1. **R&D Ab** (Biomarker for sepsis)
2. **Spectral Platforms** (Rapid diagnosis of sepsis)
3. **Velox Biosystems** (Rapid, ultra-sensitive, single-cell detection and quantification platform technology)
4. **CytoChip** (Developing a point of care IVD with its first panel for CBC)
5. **Veriskin** (Skin cancer screening)

### **Digital Health Presentations:**

1. **Eyedaptic** (Simulated Natural Vision Eyewear for AMD)
2. **HIA** (Human Interface Agent (HIA) platform for telemedicine)
3. **MediMixer** (Pediatric medication adherence)

**3:40 PM—3:50 PM -- Networking Break**

**3:50 PM— 4:40PM -- Parallel Breakout Sessions (Group I):**

**1- Maximize your Chances of Getting Government Funding:**

**Moderator:**

- **David Hood, President & CEO, Dh3 Associates**

**Panelists:**

- **Christine Densmore, M.S. Program Director: Division of Digestive Diseases and Nutrition. NIH**
- **Thomas Lobl, PhD, Entrepreneur-in-Residence, AMI-USC**
- **Patricia Weber, DrPH, Program Director, SBIR Development Center, NCI, NIH**

**2- Why Science Needs Story: How to Effectively Communicate your Technology Platform to Various Stakeholders:**

**Moderator:**

- **Gregory Zikos, Director of Business Development Strategy, AMI-USC**

**Panelists:**

- **April Beyer, CEO, LEVEL Connections.**
- **Randy Olson, Founder and Director, Story Circles Narrative Training**
- **Gaylene Xanthopoulos, Founder and President, The Leadership Edge**

**3- Meet the Angels: Optimizing your Chances of Attracting Seed Capital to your Startup**

**Moderator:**

- **Steve Goldman, Member, Keiretsu Forum and Member of the SoCalBio Innovation Catalyst Program**

**Presenters:**

- **Fred Haney, PhD, Owner, Venture Management Company**
- **Dimitri Villard, Member, Techcoast Angels**
- **Anthony Valencia, Member, Pasadena Angels**
- **Connie Harrell, President, Keiretsu Forum SoCal**
- **Vuong Trieu, PhD, CEO, Autotelic Inc.**
- **Grace Xu, Member, Pasadena Angels**

**4:40 PM—5:30 PM -- Parallel Breakout Sessions (Group II):**

**1- Business Strategy to Build an Edge and Win the Battle of Differentiation**

*Speakers will outline the processes of creating and capturing uncontested market space, winning the battle for differentiation, and making the competition irrelevant.*

**Moderator:**

- **Gregory Zikos, Director of Business Development Strategy, AMI-USC**

**Panelists:**

- **Alice Cheng, PhD, Associate, Upfront Ventures**
- **Michael Giardello, PhD, Partner, Mount Wilson Ventures**
- **Soraya M. Scroggins, Managing Director, Investment Banking and Global Healthcare, Barclays**
- **David Sykes, Business Strategy Consultant**

**2- When Can You Tap Foreign Money and How to Avoid Violating CFIUS Rules if You Do**

**Moderator:**

- Calvin Chen, CEO, CrossLinkBio

**Panelists:**

- Jasmin Patel, President, A-Connect Inc.
- Naoki Sakurai, PhD, President and CEO, Tanabe Research Laboratories

**3- Meet Local Venture Investors**

• **Moderator:**

- Alex Suh, Managing Director, California Technology Ventures

• **Presenters:**

- Troy Barring, Adventus Ventures
- Victor Subandhi, General Partner, Blangkond Ventures
- Kara Bortone, PhD, J&J Innovation
- Dan Wasserman, Mammoth Health Innovation
- Richard Weil, Partner, Mount Wilson Ventures
- Jerry Chen, Associate, Mucker Capital
- Chris Bostick, PhD, OCV Partners
- John Morrissey, Shea Ventures
- David Lee, Managing Partner, Solve Ventures
- Yoshi Fukushima, Executive VP, Takenaka Partners
- Jay Goss, Partner, WaveMaker Three-Sixty Health LP

**5:30 PM—7:30 PM -- Concluding Remarks & Networking Reception**

**7:00 PM -- Conference Adjourns**